Also called personalized medicine, this evolving field makes use of an individual’s genes, lifestyle, environment and other factors to identify unique disease risks and guide treatment decision-making.
Masimo's MightySat Medical is the first FDA-cleared pulse oximeter available to consumers without a prescription, which could disrupt the market for the notoriously inaccurate at-home devices.
MediView’s technologies utilize AR to provide clinicians with 3D “X-ray vision” guidance during minimally invasive procedures and surgeries, while also offering remote collaboration.
After training deep neural networks on around 4,000 slide images from around 40 biopsied kidney patients, UCLA engineers have virtually re-stained tissue images for speedier high-accuracy diagnostics than a human histotechnologist could support.
Researchers have achieved accuracies of 99.4% and 94.3% in two algorithmic methods for monitoring, diagnosing or ruling out Parkinson’s disease going only by individuals’ spoken words.
Screening for sepsis in children and babies has grown quickly over the past several years. As methods and approaches multiply, machine learning continues looking like an eventual first-line diagnostic option.
Researchers have used machine learning to accurately predict when a patient with chronic kidney disease will need dialysis. The technique may facilitate personalized care and optimized treatment planning.
Physicians received higher pay in 2020, with a minor compensation increase, according to the annual AMGA Medical Group Compensation and Productivity Survey.
Going head-to-head against a small group of clinicians in 50 care episodes, an AI-based smartphone app has equaled or bested the humans at triaging patients to the most appropriate site of care.
Bridgefield Capital, founded in 2015, has previously invested in such popular brands as Cirque Du Soleil, Del Monte and Quiksilver. This transaction is expected to be completed in the second half of 2025.
Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it.
The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%.
